Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 4/20 | 0.47 |
| ▸ | PLD2 | O14939 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812370 | 0.94 | PLD1 (0.47) | CTSBCTSSCTSKPLD1PLD2 | |
| SCHEMBL6812470 | 0.91 | ITGB1 (0.50) | CTSBCTSSCTSKPLD1PLD2 | |
| SCHEMBL6807468 | 0.89 | ITGB1 (0.54) | ITGB1ITGA4 | |
| SCHEMBL6807443 | 0.85 | ITGB1 (0.50) | CTSBCTSSCTSKPLD1PLD2 | |
| SCHEMBL6807415 | 0.83 | ITGA4 (0.50) | OPRK1ITGB1ITGA4 | |
| SCHEMBL5784756 | 0.83 | PLD1 (0.52) | CTSBCTSSCTSKPLD1PLD2 | |
| SCHEMBL6807110 | 0.80 | ITGA4 (0.47) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL6802695 | 0.77 | CALCRL (0.61) | PLD1PLD2CALCRLALDH1A1 | |
| SCHEMBL5780094 | 0.76 | CTSB (0.58) | CTSBCTSSCTSKPLD1PLD2 | |
| SCHEMBL6481466 | 0.75 | CTSB (0.57) | CTSBCTSSCTSKPLD1PLD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | CTSB 1720/4885CTSS 2491/4885CTSK 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.